---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Pharmacodynamics"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Pharmacodynamics. Topics: Atomoxetine plus racemic oxybutynin, single night: genioglossus responsiveness and AHI (hypopneas with 3% desaturation or arousal); Atomoxetine plus racemic oxybutynin: effects on endotypic traits; Atomoxetine alone versus atomoxetine plus racemic oxybutynin (AD036), home sleep studies (hypopneas with 4% desaturation); Choice of antimuscarinic: atomoxetine with solifenacin or biperiden (AASM scoring); 7 further topics. 11 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Atomoxetine plus racemic oxybutynin, single night: genioglossus responsiveness and AHI (hypopneas with 3% desaturation or arousal)

> “ato–oxy lowered AHI by 63% (34–86%), from 28.5 (10.9–51.6) events/h to 7.5 (2.4–18.6) events/h (P < 0.001).”
> “Genioglossus responsiveness increased approximately threefold, from 2.2 (1.1–4.7)%/cm H2O on placebo to 6.3 (3.0 to 18.3)%/cm H2O on ato–oxy (P < 0.001). Neither atomoxetine nor oxybutynin reduced the AHI when administered separately.”
> “Hypopneas were defined as reduction in flow of 30% or more from baseline, lasting at least 10 seconds, and were associated with an arousal from sleep or an oxyhemoglobin desaturation 3% or greater.”

Source: [Taranto-Montemurro et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6519859/)

<a id="topic-2.1.2.6.2-2"></a>

### Atomoxetine plus racemic oxybutynin: effects on endotypic traits

> “Compared with placebo, ato-oxy increased Vpassive by 73 [54 to 91]%eupnea (P < .001) and muscle compensation by 29 [8 to 51]%eupnea (P = .012), reduced the arousal threshold by –9 [–14 to –3]% (P = .022) and LG1 by –11 [–22 to 2]% (P = .022). Atomoxetine alone significantly reduced arousal threshold and LG1. Both agents alone improved collapsibility (Vpassive) but not muscle compensation.”
> “Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.”

Source: [Taranto-Montemurro et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7268440/)

<a id="topic-2.1.2.6.2-3"></a>

### Atomoxetine alone versus atomoxetine plus racemic oxybutynin (AD036), home sleep studies (hypopneas with 4% desaturation)

> “The apnea–hypopnea index (AHI) from a median (interquartile range) of 14.2 (5.4 to 22.3) events/h on placebo to 6.2 (2.8 to 13.6) with AD036 and 4.8 (1.4 to 11.6) with atomoxetine alone (p < .0001).”
> “AD036, but not atomoxetine alone, reduced the respiratory arousal index and improved ventilation at the respiratory arousal threshold (greater Vactive). There was a trend for total sleep time to be decreased more with atomoxetine alone than with AD036.”
> “Atomoxetine may account for the majority of improvement in OSA severity, while the addition of oxybutynin may mitigate the disruptive effect of atomoxetine on sleep and further improve ventilation.”
> “The 4% oxygen desaturation criterion was used for scoring of hypopneas and subsequent calculation of the AHI, and for calculation of the oxygen desaturation index (ODI).”

Source: [Schweitzer et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9098382/)

<a id="topic-2.1.2.6.2-4"></a>

### Choice of antimuscarinic: atomoxetine with solifenacin or biperiden (AASM scoring)

> “Neither drug combination altered the apnea/hypopnea index versus placebo (P = 0.63).”
> “Atomoxetine + biperiden hydrochloride reduces perceived sleepiness, and atomoxetine + solifenacin modestly improves upper airway function in people with OSA but to a lesser extent versus recently published atomoxetine + oxybutynin (broad M-subtype receptor selectivity) findings.”
> “All overnight in-laboratory sleep studies (polysomnography) were performed according to American Academy of Sleep Medicine guidelines.”

Source: [Aishah et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8424567/)

<a id="topic-2.1.2.6.2-5"></a>

### Contribution of the antimuscarinic component to upper airway activity and sleep consolidation

> “However, it has become clear, after multiple similar findings, that the SNRIs (atomoxetine or reboxetine) have the most important stimulatory action on the pharyngeal dilator muscles, while the antimuscarinic component has a smaller such effect.”
> “A second important contribution of the anticholinergic agent in the ato-oxy combination was discovered to be the mitigation of the wake-promoting effects caused by the SNRIs.”

Source: [Taranto-Montemurro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12713960/)

> “Oxybutynin was also found to attenuate a reduction in arousal threshold observed with atomoxetine monotherapy, raising the possibility that blocking muscarinic signaling blunts the behavioral/arousal expression of noradrenergic drive48 allowing for HMN activations while maintaining sleep.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.6.2-6"></a>

### AD109 versus atomoxetine alone over 4 weeks: respiratory parameters and total sleep time (MARIPOSA)

> “AD109 did not differ significantly from atomoxetine alone (Ato75) for most respiratory parameters, suggesting that the noradrenergic activity of atomoxetine is primarily responsible for the effect of AD109 on upper airway obstruction. However, Ato75 was more likely to disturb sleep than AD109 based on objective and subjective measurements.”
> “Total sleep time (TST) did not change with AD109 compared with placebo. However, Ato75 reduced TST by 21.5 (8.6–34.3) minutes compared with placebo (P = 0.001) and by 23.93 (8.89–38.98) and 16.09 (1.24–30.94) minutes compared with AD109 2.5/75 mg and 5/75 mg, respectively (P = 0.002 and P = 0.03).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.1.2.6.2-7"></a>

### AD109 dose response after a single night, APC-004 (hypoxic burden and AHI with 4% desaturation)

> “The primary endpoint was the reduction of HB (calculated based on AHI with four percent desaturation) and the reduction of AHI (calculated based on four percent desaturations) was a key secondary endpoint.”
> “Standard dose AD109 significantly reduced HB by 84% (p<0.0001) and AHI by 59% (p<0.0001) relative to placebo. Low dose also significantly reduced HB by 47% (p=0.0048) and AHI by 41% (p<0.05) vs placebo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.2-8"></a>

### Apnea index and hypopnea index (4% desaturation criterion) in the phase 3 trials, on-treatment estimand: company exploratory analysis

> “At week 26 in SynAIRgy, AD109 was associated with a 77.2% mean reduction from baseline in the apnea index among patients who remained on treatment (vs 20.2% on placebo), compared with a smaller mean relative reduction of approximately 45.3% in the hypopnea index (vs 12.4% on placebo). Similarly, in LunAIRo, the mean relative reduction of apnea index was 67.1% (vs 2.8% reduction on placebo), while the mean hypopnea index saw a 37.8% reduction (vs 3.1% on placebo). We believe this pattern raises the possibility that AD109 converts some complete obstructive apneas into partial obstructions (hypopneas).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.6.2-9"></a>

### REM sleep and body mass index changes in the phase 3 trials

> “In the SynAIRgy clinical trial, changes in BMI at week 26 were negligible across treatment groups; median (interquartile range) change was −0.1 (−1.1 to 0.6) with AD109 and 0.1 (−0.4 to 0.9) with placebo. Change in BMI in LunAIRo at 51 weeks was also small: median (IQR) change was -0.2 (-1.4 to 0.8) with AD109 and -0.1 (-0.9 to 0.7) with placebo. Although AD109 was associated with small reductions in weight and proportion of REM sleep, our adjusted analyses found that these changes had minimal influence on the improvement of AHI observed (Figure 33), supporting that the proposed mechanism of action of AD109 is via improvement in sleep-related neuromuscular dysfunction.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “AD109 was associated with a reduction in REM sleep, consistent with the established effects of noradrenergic, serotonergic, and tryciclic antidepressant agents. The clinical significance of pharmacologically driven REM reduction remains uncertain, and existing evidence suggests that it is not associated with impairments in cognitive performance or vigilance.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.6.2-10"></a>

### Atomoxetine label: cardiac electrophysiology

> “No large changes in QTc interval (i.e., increases >60 msec from baseline, absolute QTc >480 msec) were observed in the study. However, small changes in QTc interval cannot be excluded from this study, because the study failed to demonstrate assay sensitivity. There was a slight increase in QTc interval with increased atomoxetine concentration.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.6.2-11"></a>

### Oxybutynin label: pharmacodynamic effects on the bladder

> “In patients with conditions characterized by involuntary bladder contractions, cystometric studies have demonstrated that oxybutynin increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

Additional sources: [Gell et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41932835/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
